NCT03593434

Brief Summary

This is an observational cohort study building on an existing protocol at our institution recruiting CF patients who are 6-21 years old with one or two copies of the F508del CFTR mutation. That existing protocol seeks to enroll a total of 38 subjects; it includes three to four (three scheduled, with a fourth optional) study visits, with spirometry, LCI, UTE MRI, and 129Xe MRI being performed at each visit. This present study will utilize existing study visits for the NHLBI study, with a sub-set of 20 subjects opting-in to have all of the procedures performed twice, with an intervening ACT, during one of their study visits.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2018

Completed
22 days until next milestone

First Posted

Study publicly available on registry

July 20, 2018

Completed
10 days until next milestone

Study Start

First participant enrolled

July 30, 2018

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

March 10, 2022

Status Verified

March 1, 2022

Enrollment Period

3.4 years

First QC Date

June 28, 2018

Last Update Submit

March 8, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Effect of ACT on 129Xe MRI

    Quantify the effect of ACT on 129Xe MRI in ventilation defect percentage (%), in 20 children ages 6-21 years with CF

    one-day single study visit

Secondary Outcomes (2)

  • Effect of ACT on spirometry

    one-day single study visit

  • Effect of ACT on LCI

    one-day single study visit

Other Outcomes (1)

  • Structural changes on UTE MRI

    one-day single study visit

Interventions

This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.

Also known as: 129Xenon

Eligibility Criteria

Age6 Years - 21 Years
Sexall
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Male or female ages 6 through 21 with CF

You may qualify if:

  • Male or female between the ages of 6 through 21 years
  • CFTR genotypes as specified in NHLBI study:
  • Two copies of the F508del CFTR mutation, OR Two non-functional CFTR mutations with one of them being F508del CFTR mutation
  • Able to perform acceptable and repeatable spirometry

You may not qualify if:

  • FEV1 percent predicted of \<60%
  • pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 42229, United States

Location

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, Diseases

Study Officials

  • Jason Woods, PhD

    Children's Hospital Medical Center, Cincinnati

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD, Director, Center for Pulmonary Medicine Imaging Research, Principal Investigator

Study Record Dates

First Submitted

June 28, 2018

First Posted

July 20, 2018

Study Start

July 30, 2018

Primary Completion

December 30, 2021

Study Completion

December 30, 2021

Last Updated

March 10, 2022

Record last verified: 2022-03

Locations